Holen Sie sich die Stockscreener-App
4.03
4.95%
-0.21
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research
HC Wainwright reaffirms Buy for Vanda Pharmaceuticals stock - AD HOC NEWS
Three posters examine a treatment for a rare form of psoriasis - Stock Titan
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting - PR Newswire
Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA) - Seeking Alpha
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug - Benzinga
Vanda Pharmaceuticals says Phase III HETLIOZ study met sleep endpoint - Mugglehead Investment Magazine
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - Yahoo Finance
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PR Newswire
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360
Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com India
VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com
VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - PR Newswire
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - valueresearchonline.com
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - webull.com
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Fairbanks Daily News-Miner
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - PR Newswire
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline - finance.biggo.com
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):